VSV Packaging Service
Vesicular stomatitis virus (VSV) is a prototypic animal virus, a member of the Vesiculovirus genus in the family Rhabdoviridae. Wild type (WT) VSV transmission most occurs in animals through insect bites. Human VSV transmission is rare with much less severe disease symptoms, alike a mild flu-like illness or asymptomatic. VSV has eight main serotypes: Indiana, New Jersey, Cocal, Alagoas, Isfahan, Chandipura, Maraba, and Piry.
VSV is a bullet-shaped, enveloped virus consisting of a single strand of negative-sense RNA, which encodes five major proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and large protein (L). The simplicity of VSV genome enables its extensively application in research field. Besides, the replication of wild type VSV does not incorporate into host genome, unlike HIV or lentivector, therefore, its application is much safer. In the laboratory, the recombinant VSV (rVSV) has been engineered to target cancer cells or to stimulate immunity against diseases such as AIDS or influenza. Moreover, based on VSV backbone, ERVEBO (rVSVΔG-ZEBOV-GP) Ebola vaccine has been approved to use in human by the FDA in 2019.
VSV pseudovirus or backbone we offer
The recombinant VSV (rVSV) we provide: VSV-∆P, VSV-∆L and VSV-∆G. They can be conjugated with different reporters, such as GFP, dsRed or Luciferase, to package heterologous protein. Below is example of products we provide/customize:
Product Name | Catalog | Brief description |
Lassa Virus Glycoprotein Complex (Josiah Strain) with Luciferase | M85H4 | VSV-∆G packages Lassa Virus Glycoprotein with Luciferase reporter |
SARS-CoV-2 (Wuhan Strain) Spike with Luciferase | O21F29 | VSV-∆G packages SARS-CoV-2 Spike with Luciferase reporter |
Ebola Zaire strain GP with Luciferase | S99W4 | VSV-∆G packages Ebola virus GP with Luciferase reporter |
Rabies Virus G Fusion with Luciferase | U13T93 | VSV-∆G packages Rabies Virus G Fusion with Luciferase reporter |
HCV E1E2 with Luciferase | P2R77 | VSV-∆G packages HCV E1E2 with Luciferase reporter |
Protease Inhibitor Screening | Customized | Nirmatrelvir screening by VSV-∆P, VSV-∆L |
General Workflow
Service Details
Cat. No. | Scale | Application | Typical Titer | Volume | Price | Turnaround |
H57F61-1 | Supernatant | Cell culture & in vivo | > 2E+6 TCID50/ml | 1 ml | $560 | 14 – 20 days |
H57F61-2 | Concentrated | > 1E+8 TCID50/ml | 100 ul | $2690 | 14 – 30 days |
- The volume and titer can be customized per request.
Quality Control
As above mentioned, rVSV encodes a fluorescent or reporter (such as luciferase) protein, we would perform transduction test to detect corresponding fluorescence or read reporter luciferase signal (refer the titration of our VSV pseudovirus reporters with one example below).
We have a large panel of antibody you can choose from to validate VSV virus carrying your gene of interest using our BLI/SPR Analytical Service with extra cost. Among these antibodies, some are neutralizing and capable to block the entrance of VSV virus to target cells. We provide the service of Neutralization Evaluation.